Document Detail

Bail-out transcatheter aortic valve implantation to reduce severe acute aortic regurgitation in a failing homograft secondary to HeartMate II ventricular assistance device.
MedLine Citation:
PMID:  24445212     Owner:  NLM     Status:  Publisher    
Left ventricular assistance with surgically implanted pump devices like the HeartMate may be crucial in selected patient with end-stage heart failure. However, mainly due to its high aortic output, the pump itself may induce severe aortic regurgitation that could result in paradoxycal worsening of the anterograde perfusion after the initiation of the support. Surgical or percutaneous occlusion of the aortic valve has proved useful in these kinds of patients. Here we present a successful case of bail-out CoreValve implantation after HeartMate II positioning complicated by acute severe aortic regurgitation in a patient with a failing homograft and end-stage ventricular dysfunction, ineligible for heart transplanation.
Flavio Ribichini; Giuseppe Faggian; Gabriele Pesarini; Aldo Milano; Leonardo Gottin; Corrado Vassanelli
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-26
Journal Detail:
Title:  Cardiovascular revascularization medicine : including molecular interventions     Volume:  -     ISSN:  1878-0938     ISO Abbreviation:  Cardiovasc Revasc Med     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2014-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238551     Medline TA:  Cardiovasc Revasc Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic Accuracy of Kato-Katz, FLOTAC, Baermann, and PCR Methods for the Detection of Light-Inten...
Next Document:  Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.